Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beigene Ltd ADR
(NQ:
BGNE
)
198.59
+1.31 (+0.66%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership
August 12, 2023
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies...
Via
Talk Markets
Growing Competition in Hematology, Aesthetics Complicates AbbVie's Post-Humira Landscape, Analyst Says
July 25, 2023
William Blair has initiated coverage on AbbVie Inc (NYSE: ABBV) with a
Via
Benzinga
BeiGene's Brukinsa Positioned as Preferred BTK Inhibitor: Analyst Says Survey Supports Bullish View
July 17, 2023
Citi initiated coverage on BeiGene Ltd (NASDAQ: BGNE) with a price target of $275 and a B
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 17, 2023
July 17, 2023
Via
Benzinga
Why Are BeiGene Shares Trading Lower Today
July 11, 2023
BeiGene Limited (NASDAQ: BGNE) shares are trading lower after the company mutually agreed to
Via
Benzinga
What's Happening With Beigene Shares During Wednesday's Session
June 21, 2023
Beigene Ltd (NASDAQ: BGNE) shares are trading lower by 3.41% to $185.03 Wednesday morning on downward momentum following Tuesday weakness.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023
June 30, 2023
Via
Benzinga
Why This BeiGene Analyst Slashes Forecast By Almost 42%
June 30, 2023
BeiGene Ltd (NASDAQ: BGNE) declined in early trading on Friday, maintaining its downward trajectory through the week amid weakness in Chinese stocks.
Via
Benzinga
NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday
June 30, 2023
Truist Securities boosted the price target for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $125 to $140. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. BioMarin Pharmaceutical...
Via
Benzinga
Recap: BeiGene Q1 Earnings
May 04, 2023
Via
Benzinga
BeiGene's Tislelizumab/Chemo Combo Hits Primary Goal In Gastric Cancer Study
April 20, 2023
Via
Benzinga
Why BeiGene Stock Jumped Thursday
April 06, 2023
A collaboration deal helped send the Chinese biotech stock higher.
Via
The Motley Fool
AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent
June 15, 2023
BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics
Via
Benzinga
Why MicroVision Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket
June 15, 2023
Gainers EdtechX Holdings Acquisition Corp. II (NASDAQ: EDTX) shares gained 139.8% to $26.54 in pre-market trading.
Via
Benzinga
Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 15, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting
May 25, 2023
Via
Benzinga
BeiGene Earnings Perspective: Return On Capital Employed
March 02, 2023
Via
Benzinga
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
May 22, 2023
Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor...
Via
Benzinga
What's Going On With Immix Biopharma Stock Today
May 03, 2023
Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG'
Via
Benzinga
3 Top Biotech Stocks Defying the Bear Market
April 25, 2023
All three companies have therapies with strong sales potential.
Via
The Motley Fool
7 Biotech Stocks That Could Cure Your Portfolio Woes
April 19, 2023
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.
Via
InvestorPlace
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials
April 13, 2023
This month, H.C. Wainwright & Co.
Via
Benzinga
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
April 11, 2023
A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global...
Via
Benzinga
Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors
April 11, 2023
This month, Enlivex Therapeutics Ltd.
Via
Benzinga
Silicon Valley Bank Collapse Might Have Limited Impact On Asia, But Confidence Seems Shaken
March 13, 2023
Some Asian firms have disclosed cash deposits at troubled U.S. lender Silicon Valley Bank (NASDAQ: SIVB), known for its deep ties with the healthcare and tech sector. Most emphasized that the amounts...
Via
Benzinga
Nasdaq, S&P 500 Futures Rebound In New Trading Week But Rising Bond Yields Remain A Risk
February 27, 2023
US stocks are coming off a lackluster week and early indications suggest a reversal in sentiment in the new trading week. While rising bond yields could be a cause of concern, the recent weakness could...
Via
Benzinga
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
February 25, 2023
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between...
Via
Talk Markets
Five Best And Worst Performing Healthcare Stocks In January 2023
February 05, 2023
After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and...
Via
Talk Markets
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
January 26, 2023
A disappointing fourth-quarter performance has some investors worried about the giant healthcare conglomerate's outlook.
Via
The Motley Fool
Five Best And Worst Performing Healthcare Stocks In December 2022
January 22, 2023
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst...
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.